The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes
- Status
- RecruitingResults none
- Why it is watched
- non-weight indication: liver
- Who it enrolls
- age 18 Years to 75 Years; BMI ≥25 required; conditions: Type 2 Diabetes Mellitus (T2DM); Semaglutide; Caloric Restriction
- Interventions
- semaglutide; caloric restriction
- Conditions
- Type 2 Diabetes Mellitus (T2DM); Semaglutide; Caloric Restriction
- Phase and size
- Phase 4 · 100 participants
- Dates
- Start 2023-02-10
Primary completion 2026-06-30 - Sponsor
- Second Affiliated Hospital of Nanchang University (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- HbA1cFrom enrollment to the end of treatment at 12 weeks
- FPGFrom enrollment to the end of treatment at 12 weeks
- 2hPGFrom enrollment to the end of treatment at 12 weeks
02Eligibility
Who can take part
Inclusion Criteria: 1. Age 18-75 years; 2. BMI≥25 kg/m²; 3. Diagnosed as type 2 diabetes mellitus patients according to the "Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition)"; 4. HbA1c≤8.5%; 5. Duration of diabetes ≤3 months, and no use of antihyperglycemic drugs; 6. Willing to participate in this study, and after full informed consent, agrees to strictly follow the treatment plan and promises to attend follow-up visits on time, and signs the informed consent form. Exclusion Criteria: 1. BMI \< 25 kg/m²; 2. Age \< 18 years, or \> 75 years; 3. History of type 1 diabetes, acute pancreatitis, or diabetes secondary to pancreatectomy; 4. History of bariatric surgery or planned bariatric surgery, or currently attempting weight loss within the past 3 months, or use of weight-loss medications within the past 3 months; 5. Use of GLP-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors, thiazolidinediones, or other related drugs within the past 3 months; 6. Pregnant or breastfeeding women, or those planning to conceive during the study period; 7. Patients with severe diseases of important organ systems, such as severe cardiovascular and cerebrovascular diseases, respiratory diseases, gastrointestinal diseases, renal insufficiency, hematologic diseases, neurological diseases, or malignancies; 8. Personal or family history of medullary thyroid carcinoma; 9. Patients with severe mental disorders or communication barriers that prevent accurate understanding of the study content and compliance with the trial procedures.
03Change log
Registry changes
No changes recorded since the trial was added.